{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:25:28Z","timestamp":1770740728633,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.clinthera.2016.03.031","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T20:33:59Z","timestamp":1460579639000},"page":"1299-1313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes"],"prefix":"10.1016","volume":"38","author":[{"given":"Sven","family":"Kohler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshin","family":"Salsali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Hantel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kaspers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J.","family":"Woerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uli C.","family":"Broedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"83","key":"10.1016\/j.clinthera.2016.03.031_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"78","key":"10.1016\/j.clinthera.2016.03.031_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab Vasc Dis Res"},{"issue":"3396","key":"10.1016\/j.clinthera.2016.03.031_bib3","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Haering","year":"2013","journal-title":"Diabetes Care"},{"issue":"208","key":"10.1016\/j.clinthera.2016.03.031_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1650","key":"10.1016\/j.clinthera.2016.03.031_bib5","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"Haering","year":"2014","journal-title":"Diabetes Care"},{"issue":"147","key":"10.1016\/j.clinthera.2016.03.031_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"1815","key":"10.1016\/j.clinthera.2016.03.031_bib7","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"issue":"420","key":"10.1016\/j.clinthera.2016.03.031_bib8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2016.03.031_bib9","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added-on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2016.03.031_bib10","unstructured":"FDA guidance: reviewer guidance conducting a clinical safety review of a new product application and preparing a report on the review. February 2005. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm072974.pdf. Last accessed March 23, 2015."},{"issue":"721","key":"10.1016\/j.clinthera.2016.03.031_bib11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12081","article-title":"A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes","volume":"15","author":"Ferrannini","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"331","key":"10.1016\/j.clinthera.2016.03.031_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus","volume":"4","author":"Heise","year":"2013","journal-title":"Diabetes Ther"},{"issue":"613","key":"10.1016\/j.clinthera.2016.03.031_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks\u05f3 treatment with empagliflozin once daily in patients with type 2 diabetes","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"613","key":"10.1016\/j.clinthera.2016.03.031_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/jdi.12110","article-title":"Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks\u05f3 treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus","volume":"4","author":"Kanada","year":"2013","journal-title":"J Diabetes Investig"},{"issue":"1154","key":"10.1016\/j.clinthera.2016.03.031_bib15","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"369","key":"10.1016\/j.clinthera.2016.03.031_bib16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"621","key":"10.1016\/j.clinthera.2016.03.031_bib17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12325-014-0126-8","article-title":"Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial","volume":"31","author":"Kadowaki","year":"2014","journal-title":"Adv Ther"},{"issue":"691","key":"10.1016\/j.clinthera.2016.03.031_bib18","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1493","key":"10.1016\/j.clinthera.2016.03.031_bib19","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.clinthera.2015.05.001","article-title":"Pharmacokinetics and pharmacodynamic properties and tolerability of single- and multiple-dose once-daily empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Chinese patients with type 2 diabetes","volume":"37","author":"Zhao","year":"2015","journal-title":"Clin Ther"},{"issue":"4015","key":"10.1016\/j.clinthera.2016.03.031_bib20","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.2337\/dc13-0663","article-title":"Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes","volume":"36","author":"Ferrannini","year":"2013","journal-title":"Diabetes Care"},{"issue":"306","key":"10.1016\/j.clinthera.2016.03.031_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12325-015-0198-0","article-title":"Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study","volume":"32","author":"Kadowaki","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2016.03.031_bib22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.diabres.2015.05.044","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes","volume":"110","author":"Haering","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"1773","key":"10.1016\/j.clinthera.2016.03.031_bib23","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.clinthera.2015.05.511","article-title":"Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes","volume":"37","author":"Kovacs","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2016.03.031_bib24","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/dme.12814","article-title":"Empagliflozin as add-on to metformin in people with type 2 diabetes","volume":"32","author":"Merker","year":"2015","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2016.03.031_bib25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","article-title":"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial","volume":"14","author":"Roden","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2016.03.031_bib26","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"815","key":"10.1016\/j.clinthera.2016.03.031_bib27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40264-014-0213-4","article-title":"Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events","volume":"37","author":"Ptaszynska","year":"2014","journal-title":"Drug Saf"},{"issue":"1149","key":"10.1016\/j.clinthera.2016.03.031_bib28","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00228-014-1730-x","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis","volume":"70","author":"Yang","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.03.031_bib29","doi-asserted-by":"crossref","unstructured":"Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34:S279\u2013S284.","DOI":"10.2337\/dc11-s231"},{"issue":"505","key":"10.1016\/j.clinthera.2016.03.031_bib30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/14740338.2015.1006625","article-title":"Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes","volume":"14","author":"Scheen","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2016.03.031_bib31","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Jardiance (empagliflozin) US Prescribing Information; 2014."},{"issue":"479","key":"10.1016\/j.clinthera.2016.03.031_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","article-title":"Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complications"},{"issue":"683","key":"10.1016\/j.clinthera.2016.03.031_bib33","first-page":"683","article-title":"Emerging treatments in type 2 diabetes: focus on canagliflozin","volume":"10","author":"Rosiak","year":"2014","journal-title":"Ther Clin Risk Manag"},{"issue":"587","key":"10.1016\/j.clinthera.2016.03.031_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"2599","key":"10.1016\/j.clinthera.2016.03.031_bib35","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"Skrti\u0107","year":"2014","journal-title":"Diabetologia"},{"issue":"262","key":"10.1016\/j.clinthera.2016.03.031_bib36","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2016.03.031_bib37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"issue":"2849","key":"10.1016\/j.clinthera.2016.03.031_bib38","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"S28","key":"10.1016\/j.clinthera.2016.03.031_bib39","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","article-title":"Adverse effects and safety of SGLT-2 inhibitors","volume":"40","author":"Halimi","year":"2014","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clinthera.2016.03.031_bib40","first-page":"S360","article-title":"Potential relevance of changes in haematocrit to changes in lipid parameters with empagliflozin in patients with type 2 diabetes","volume":"58","author":"Lund","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2016.03.031_bib41","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2215\/CJN.09750913","article-title":"Renal control of calcium, phosphate, and magnesium homeostasis","volume":"10","author":"Blaine","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2016.03.031_bib42","unstructured":"Janssen Pharmaceuticals Inc. Invokana (canagliflozin) US Prescribing Information; 2014."},{"issue":"E831","key":"10.1016\/j.clinthera.2016.03.031_bib43","doi-asserted-by":"crossref","first-page":"E831","DOI":"10.1152\/ajpendo.00296.2009","article-title":"Facilitative glucose transporter 9, a unique hexose and urate transporter","volume":"297","author":"Doblado","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"391","key":"10.1016\/j.clinthera.2016.03.031_bib44","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816301680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816301680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T06:56:25Z","timestamp":1536821785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816301680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0149291816301680"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.031","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}